In melanoma, other immunological events seem to affect response to treatment, such as pre-existing CD8+ T cell infiltration at the invasive tumor margin, which is associated with the expression of PD-1 and PD-L1 immune inhibitory axis and correlated with response to pembrolizumab.19 The gene discussed is CD8A; the disease is neoplasm.